Potassium chloride preparations and fecal blood loss. A parallel study with a 10 percent solution and a non-enteric-coated waxy-matrix tablet.
Concentrated potassium chloride produces ulceration of the gastrointestinal mucosa. Dilute solutions are frequently not acceptable to the patient. A tablet containing potassium chloride crystals suspended in a waxy matrix has been developed to avoid these drawbacks. We measured fecal blood loss by a radioactive chromium technique on 20 subjects during five days while they were given potassium chloride, 40mEq/day; ten subjects took a 10% solution; the others the waxy-matrix tablet. Fecal blood loss did not differ significantly between these groups. Mean fecal blood losses in both groups were slightly increased during the potassium chloride administration but never exceeded acceptable normal limits.
D000328:Adult; D002860:Chromium Radioisotopes; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005243:Feces / Q000032:analysis*; D006801:Humans; D007258:Informed Consent; D007413:Intestinal Mucosa / Q000187:drug effects; D008297:Male; D008551:Melena / Q000139:chemically induced* / Q000175:diagnosis; D008875:Middle Aged; D009780:Occult Blood; D011189:Potassium Chloride / Q000008:administration & dosage / Q000009:adverse effects*; D012996:Solutions; D013608:Tablets, Enteric-Coated
D002860:Chromium Radioisotopes; D003692:Delayed-Action Preparations; D012996:Solutions; D013608:Tablets, Enteric-Coated; D011189:Potassium Chloride